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1. INTRODUCTION 
Extracellular nucleotides have major roles in the 
activity of neural cells. They act as transmitters or 
modulators in most nerve types in the peripheral and 
central nervous system. Furthermore, they also act as 
important mediators in neuronal-glia or glia-glia 
communication and are trophic factors participating in cell 
differentiation, proliferation, migration and death (1, 2). 
Nucleotide-mediated signaling mechanisms and specific 
receptor subtypes have been shown to be involved in 
various pathological conditions including brain trauma and 
ischaemia, neurodegenerative diseases involving 
neuroimmune and neuroinflammatory reactions, as well as 
in neuropsychiatric diseases (3). 
ABSTRACT: Nucleotides are important signalling 
molecules in both the peripheral and central nervous 
system. However, the in vitro study of their receptors 
can be hampered by the heterogeneity of primary 
neuronal cultures. The use of clonal neuroblastoma cell 
lines allows to circumvent this difficulty, so these lines 
are often used as a model to analyze the properties, 
regulation and physiological role of nucleotide receptors 
in neural tissues. Expression studies indicated the 
presence of P2Y1, P2Y6, P2Y11, P2Y13, P2X1, P2X4, 
P2X5, P2X6 and P2X7 proteins in SK-N-MC cells. 
Functional analyses showed transient [Ca2+]i increases 
upon application of ADP, 2-MeSADP or ADPβS. 
Responses to these agonists seem to be mediated by a 
P2Y1 receptor, as demonstrated by the almost complete 
blockade exerted by the P2Y1-selective antagonist 
MRS2179. ATP was also able to induce [Ca2+]i 
increases in SK-N-MC cells. Responses to ATP were 
partially blocked by MRS2179 and the P2X antagonist 
TNP-ATP, thus suggesting that ATP can interact with 
two different P2 receptors: a P2Y1 receptor, inhibited by 
MRS2179, and a TNP-ATP sensitive P2X receptor. To 
characterize the P2X receptor responsible for the 
MRS2179-resistant component of the ATP response, we 
analyze the effect of several P2X agonists on [Ca2+]i. 
Cells did not show responses to either α,β-meATP or 
BzATP, although [Ca2+]i increases could be observed 
when cells were challenged with CTP. Both the 
response to CTP and the MRS2179-resistant component 
of ATP response were potentiated by ivermectin. Such 
pharmacological profile is consistent with the presence 
of a functional P2X4 receptor in SK-N-MC cell line. 
 
RESUMEN: Los nucleótidos son importantes 
moléculas señalizadoras en el sistema nervioso. El 
estudio in vitro de sus receptores puede verse 
obstaculizado por la heterogeneidad de los cultivos 
neuronales. El uso de líneas celulares de neuroblastoma 
permite eludir esta dificultad y dichas líneas se utilizan 
frecuentemente como un modelo con el que analizar las 
propiedades, regulación y función de los receptores de 
nucleótidos en tejidos neurales. Estudios de expresión 
indicaron la presencia de proteínas P2Y1, P2Y6, P2Y11, 
P2Y13, P2X1, P2X4, P2X5, P2X6 y P2X7 en las células 
SK-N-MC. Análisis funcionales mostraron incrementos 
transitorios de [Ca2+]i tras la aplicación de ADP, 2-
MeSADP o ADPβS, respuestas que parecen estar 
mediadas a través un receptor P2Y1, como se pone de 
manifiesto por el bloqueo casi total ejercido por el 
antagonista selectivo P2Y1, MRS2179. El ATP también 
indujo incrementos de [Ca2+]i en las células SK-N-MC, 
siendo su respuesta parcialmente bloqueada por 
MRS2179 y por el antagonista P2X TNP-ATP, lo que 
sugiere que el ATP puede interactuar con dos receptores 
P2 diferentes: un receptor P2Y1, inhibido por MRS2179, 
y un receptor P2X sensible a TNP-ATP. Se caracterizó 
el receptor P2X analizando el efecto de varios agonistas 
en la [Ca2+]i. Ninguna célula mostró respuestas a α,β-
meATP o BzATP, aunque se observaron incrementos de 
[Ca2+]i cuando las células fueron estimuladas con CTP. 
Tanto la respuesta a CTP como el componente de la 
respuesta a ATP resistente a MRS2179, se potenciaron 
en presencia de ivermectina. Todos estos datos sugieren 
la presencia de un receptor P2X4 funcional en las 
células SK-N-MC. 
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Nucleotide effects are mediated trough two subclasses 
of specific cell surface receptors, ionotropic P2X and 
metabotropic P2Y receptors (4). Seven distinct P2X 
subtypes (P2X1-7) have been cloned from mammalian 
species, showing a topology that includes two 
transmembrane spanning regions, a large extracellular loop 
and intracellular N and C termini. These proteins assemble 
into ATP activated channels either as homomers or 
heteromers, each functional receptor containing at least 
three monomers. P2X receptor activation results in Na+ 
and Ca2+ influx across the cell membrane, which leads to 
depolarization. Membrane depolarization subsequently 
activates voltage-operated calcium channels, thus causing 
accumulation of Ca2+ ions in the cytoplasm. Although the 
detailed signalling mechanism have not been established 
for most P2X receptor subtypes, it is well known that 
cytoplasmic Ca2+ elevation triggers a variety of 
intracellular events, in part, trough activation of mitogen-
activated protein kinases (MAPKs), protein kinase C 
(PKC) and calmodulin (5-7). 
The P2Y receptors are classical 7-transmembrane 
domain metabotropic receptors coupled to G proteins. 
Currently, eight P2Y receptors subtypes (P2Y1, 2, 4, 6, 11, 12, 
13, 14) have been cloned. P2Y1, 11, 12, 13 receptors are 
selectively activated by adenine nucleotides, whereas P2Y4 
and P2Y6 are stimulated by pyrimidines. The P2Y2 
receptor responds equally well to purine and pyrimidine 
triphosphates (ATP and UTP) and P2Y14 is a sugar-
nucleotide (UDP-glucose) responding receptor. Most 
members of the P2Y family (P2Y1, 2, 4, 6, 11) are functionally 
coupled to Gq/11 proteins and stimulate phosphoinositide-
specific phospholipase C, resulting in the formation of 
inositol-(1,4,5)-trisphosphate and diacylglycerol with 
subsequent mobilization of Ca2+ from internal stores. 
P2Y11 receptor additionally stimulates adenylate cyclase, 
whereas P2Y12, P2Y13 and P2Y14 promote Gi/0 inhibition of 
adenylate cyclase activity. The stimulation of several P2Y 
receptors is also commonly associated with the activation 
of MAPKs (in particular extracellular signal-regulated 
protein kinase 1/2, ERK1/2). Other classes of protein, such 
as phospholipases A2 and D, PKC or phosphatidylinositol 
3-kinase, can be also activated according to the cell 
context and the particular P2Y subtype (5, 8, 9). 
Several neuroblastoma cell lines, each originating from 
a single cell that has been isolated from a spontaneously 
occurring or induced tumor of the nervous system, are now 
available and can be maintained in culture infinitely. 
Neuroblastoma derived cell lines have been used as an in 
vitro model for the study of a variety of neurotransmitter 
receptors including those for nucleotides. Indeed, the P2Y2 
receptor was originally cloned from the mouse 
neuroblastoma/rat glioma hybrid line NG108-15 (10). 
Further studies have revealed the presence in these cells of 
the P2X7 receptor and metabotropic receptors other than 
the P2Y2 subtype (11, 12). Functional P2X7 receptors can 
be also detected in different human neuroblastoma lines 
(13, 14) as well as in the mouse Neuro-2a neuroblastoma 
cells (6, 15). In addition, a range of cell lines of both 
mouse and human neuroblastoma origin have been shown 
to functionally express pyrimidine selective P2Y receptors 
(16-18). 
SK-N-MC human neuroblastoma are known to 
constitutively express adrenergic α2C, β1 and β3 (19, 20), 
dopamine D1 (21), neuropeptide Y1 (22) and muscarinic 
M1 receptors (23). The regulation and signalling pathways 
activated by these receptors have been extensively 
investigated using SK-N-MC cells as a model (24-28). SK-
N-MC cell line also served to analyze the integration or 
cross-communication of signals upon activation of 
different types of neurotransmitter receptors (29). More 
recently, SK-N-MC has been used as a parental line with 
which generate cellular lines that stably overexpress 
proteins of interest in the study of distinct 
neurodegenerative disorders, such as the amyloid 
precursor protein APP (30), carboxyl-terminal fragments 
of the APP protein (31, 32), or different mutated forms of 
the Parkin protein (33). 
Earlier experiments showed that ATP and other 
nucleotides are able to induce response (phosphoinositide 
hydrolysis and formation of inositol phosphates) in the 
SK-N-MC cells, thus indicating the presence of not fully 
characterized P2 receptors in this neuroblastoma cell line 
(23). 
In the present study we have analyzed the presence of 
functional P2 receptors in the human neuroblastoma SK-
N-MC cells. If such receptors were present in these cells, 
SK-N-MC cell line could serve as a useful model to 
analyze several aspects of the signalling mediated through 
nucleotide receptors in neural tissues. This includes the 
regulation and transduction pathways activated by P2 
receptors, their interaction with other neurotransmitter 
receptors or their putative relationship with proteins 
involved in neurodegenerative processes 
2. MATERIALS AND METHODS 
2.1. Materials 
2-methylthyo-adenosine-5'-diphosphate (2-MeSADP), 
α,β-methylene-adenosine 5'-triphosphate (α,β-meATP), 
ADP, adenosine-5'-0-(2-thiodiphosphate) (ADPβS), ATP, 
2'(3')-O-(4-benzoylbenzoyl) adenosine 5'-triphosphate 
(BzATP), CTP, pyridoxalphosphate-6-azophenyl-2',4'-
disulphonic acid (PPADS), 2',3'-O-(2,4,6-
trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP), 
UDP, UTP and ivermectin were purchased from Sigma (St 
Louis, Missouri, USA). N6-methyl-2'-deoxyadenosine-
3',5'-bisphosphate (MRS2179) was purchased from Tocris 
Cookson (Bristol, UK). Products for cell culture, 
immunocytochemical and western-blot studies and 
fluorescent probes are included in the specific methods 
section. Other analytical grade reagents were purchased 
from Merck (Darmstadt, Germany). 
2.2. Cell culture 
The SK-N-MC human neuroblastoma cell line (HTB-
10) was purchased from the American Type Culture 
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Collection (ATCC, Barcelona, Spain). Cells were grown in 
monolayer in 10-cm plastic culture dishes (BD Falcon, 
Erembodegem, Belgium) at 37 ºC in a humidified 
atmosphere of 95% air and 5% CO2. Culture medium was 
minimum essential medium (Gibco, Rockville, MD, USA) 
supplemented with 10% heat-inactivated fetal calf serum 
(Gibco), 2 mM glutamine, 1 mM sodium pyruvate, non-
essential amino acids (alanine, glutamic acid, aspartic acid, 
proline and asparagine, each at 0.4 mM), 100 units/mL 
penicillin, 0.1 mg/ml streptomycin and 0.25 µg/mL 
amphotericin B (Sigma). 
Cells were subcultured about 2 times a week: culture 
medium was removed and discarded and the cell layer was 
rinsed two times with 2 mL of a solution containing 0.25% 
(w/v) trypsin and 0,02% (w/v) EDTA in Hank's Balanced 
Salt Solution with phenol red (Sigma). Then, culture 
dishes were placed in an incubator for 1 min at 37º to 
allow cells to detach. After that, 5 mL of the culture 
medium were added to the dishes and cells were aspirated 
by gently pippeting. Cells were counted in a Neubauer 
chamber using the trypan blue exclusion test and 
appropriate aliquots of the cell suspension were taken for 
the immunocitochemical, western blot or calcium imaging 
assays. Finally, 1 mL of the cell suspension was added to a 
new culture dish containing 9 mL of the culture medium 
and cells were maintained at 37°C in 5% CO2. 
2.3. Immunocytochemical assays 
Cells were plated at a density of 200,000 cells/mL on 
glass coverslips precoated with 0.1 mg/mL poly-L-lysine 
(Biochrom AG, Berlin Germany) and maintained in a 
humidified incubator at 37 ºC in 5% CO2 for 2-3 days 
before they were used in the immunocytochemical 
experiments. Cover slips with the SK-N-MC cells attached 
were then treated with 4% (w/v) p-formaldehyde (Sigma) 
for 15 min, washed twice with phosphate-buffered saline 
(PBS) (composition mM: NaCl 137, KCl 2.6, KH2PO4 1.5, 
Na2HPO4 8.1, pH 7.4) and incubated for 1 h in PBS 
containing 3% (w/v) bovine serum albumine (BSA), 0.1% 
(v/v) Triton X-100 and 5% (v/v) normal goat or donkey 
serum (Sigma). Cells were washed three times with 
PBS/BSA and incubated with the primary antibody for 1 h 
at 37º C. Primary antibodies assayed were: rabbit anti-
P2Y1 (serum at 1:100 dilution) (Alomone labs, Jerusalem, 
Israel), rabbit anti-P2Y2 (1:200) (Chemicon International, 
Temecula, CA, USA), rabbit anti-P2Y4 (1:100) (Chemicon 
International), rabbit anti-P2Y6 (1:100) (Alomone labs), 
rabbit anti-P2Y11 (1:100) (Alomone labs), rabbit anti-
P2Y12 (1:100) (Alomone labs), rabbit anti P2Y13 (1:50) 
(Alomone labs), rabbit anti-P2X1 (1:100) (Chemicon 
International), guinea-pig anti-P2X2 (1:250) (Chemicon 
International), guinea-pig anti-P2X3 (1:500) (Chemicon 
International), rabbit anti-P2X4 (1:100) (Alomone labs), 
rabbit anti-P2X5 (1:200) (Alomone labs), rabbit anti-P2X6 
(1:100) (Alomone labs) or rabbit anti-P2X7 (intracellular 
epitope, 1:100 dilution) (Alomone labs). All the antibodies 
used in this work were polyclonal and most of them were 
raised against the corresponding human protein. In some 
cases, antibodies against the rat protein were also used (if 
it was the case, cross reactivity with the human protein has 
been verified by the manufacturer). Next, covers were 
washed three times with PBS/BSA and incubated for 1 h at 
37ºC with the secondary antibodies: donkey anti-rabbit 
IgG coupled to Cy3 (1:400) (Jackson Immunoresearch, 
West Grove, PA, USA) or fluorescein conjugated goat anti 
guinea-pig IgG (1:64) (Sigma). Then, covers were washed 
three times with PBS and mounted following standard 
procedures. Control experiments of nonspecific staining 
were performed without primary antibody or by 
preadsorption of the primary antibody with the 
immunizing peptide.  
Fluorescent images were taken using a NIKON TE-200 
microscope equipped with a S Fluor 40X objective (oil, 
1.3 NA) a mercury lamp light source, fluorescein and 
rhodamine Nikon filter sets and a CCD camera (Kappa 
ACC 1) controlled by Kappa ImageBase software (Kappa 
opto-electronics, Gleichen, Germany). 
2.4. W estern blot 
Cells were seeded on 10-cm plastic Petri dishes (BD 
Falcon) at a density of 400,000 cells/mL and maintained at 
37 ºC in 5% CO2 for 2-3 days before any treatment. 
Western blot analysis were performed using protein 
extracted from the SK-N-MC cells by homogenization in a 
buffer containing 100 nM HEPES (pH 7.4), 0.5 mM 
EDTA, 50 µg/ml phenylmethylsulfonyl fluoride, 0.5 µg/ml 
leupeptine, 0.5 µg/ml pepstatine, 0.2 M NaCl and 1% (v/v) 
Triton X-100. The samples were homogenized at 4°C and 
protein content determined by Bradford assay. Total 
protein (40 µg) was electrophoresed on 10% SDS-
polyacrylamide gels and transferred to nitrocellulose 
membranes (Whatman, Maidestone, UK). The membranes 
were blocked with 5% nonfat dried milk for 1 h at room 
temperature and further incubated overnight at 4ºC with 
the different P2 receptor antibodies at a dilution of 1:500. 
Blots were then washed and incubated for 1 h at room 
temperature with the corresponding secondary antibody 
coupled to horseradish peroxidase (DakoCytomation, 
Glostrup, Denmark). Protein bands were detected with 
enhanced chemoluminiscence detection (Perkin Elmer, 
Boston, MA, USA). Incubation with the control peptide 
was made following the manufacturer instructions. 
2.5. Calcium imaging 
Cells were plated at a density of 200,000 cells/mL on 
glass coverslips precoated with 0.1 mg/mL poly-L-lysine 
(Biochrom) and maintained in a humidified incubator at 37 
ºC in 5% CO2 for 2-3 days before they were used in the 
calcium imaging experiments. Cells attached to coverslips 
were then washed with Locke’s solution (composition in 
mM: NaCl, 140; KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.2; 
CaCl2, 2.5; glucose, 5.5; HEPES, 10; pH 7.4) 
supplemented with 1 mg/mL BSA and loaded with 5 µM 
Fura-2 AM (Molecular Probes, Eugene, OR, USA) for 30 
min at 37 ºC. Next, the coverslips were washed with 
Locke’s medium and mounted in a small superfusion 
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chamber on the stage of a Nikon TE-200 microscope. Cells 
were superfused with Locke’s solution, and different 
agonists of the P2 receptors were applied in 30s pulses. 
When the experiments were performed using P2 receptor 
antagonists (MRS2179, TNP-ATP) or potentiators 
(ivermectin), these compounds were superfused for 2 min 
before the application of the corresponding agonist. 
Cells were alternately excited at 340 and 380 nm, these 
wavelengths corresponding to the fluorescence peaks of 
Ca2+-saturated and Ca2+-free Fura-2 solutions. The 
wavelength of the incoming light was selected with the aid 
of a Lambda 10-2 optical filter changer (Sutter Instrument, 
Novato, CA, USA) and emitted light was isolated with a 
dichroic mirror (430 nm) and a 510 nm bandpass filter 
(Omega Optical). Cells were imaged through a NIKON 
40X lens (S Fluor 1.3 oil iris) and 12-bit images were 
acquired using an ORCA-ER C 47 42-80 camera from 
Hamamatsu (Hamamatsu City, Japan) controlled by 
MetaFluor 6.2r6 PC software (Universal Imaging Corp., 
Cambridge, UK). Time course data represent the average 
light intensity in a small elliptical region inside each cell. 
Background and autofluorescence components were 
subtracted at each wavelength and the 340/380 ratio was 
calculated. The data are represented as the normalized 
F340⁄F380 ﬂuorescence ratio, which increases as [Ca2+]i 
increases. 
3. RESULTS 
3.1. Immunological characterization of P2X  subunits in 
SK-N-MC cells 
In order to investigate the presence of native purinergic 
receptors in the SK-N-MC cells, the expression of P2X 
subunits was analyzed by using commercially available 
subunit-specific antibodies.  
Western blot experiments demonstrate that most of the 
P2X subunits are expressed in SK-N-MC cells, as bands 
corresponding to monomeric P2X1, P2X4, P2X5, P2X6 
and P2X7 proteins can be immunodetected (results not 
shown). 
As expected, immunocytochemical detection of P2X 
subunits correlated well with the results obtained by 
western blot. All P2X subunit antibodies, except that for 
the P2X2 and P2X3 subtypes, labeled the SK-N-MC cells. 
Immunostaining was specific as it disappeared when 
antibodies were pre-adsorbed with the corresponding 
antigen peptide (Figure 1). 
 
Figure 1. Immunological detection os P2X receptor subunits in 
SK-N-MC cells. Fluorescence image of SK-N-MC cells labeled 
with anti-P2X1 (A), anti-P2X4 (C), anti-P2X5 (E), anti-P2X6 (G) 
and anti-P2X7 (I) antibodies. To confirm a specific 
immunoreaction, primary antibodies used in A, C, E, G and I 
were pre-absorbed with the corresponding control peptide and 
immunostaining are shown in B, D, F, H and J, respectively. 
Scale bar= 20 µm in all micrographs. 
3.2. Immunological characterization of P2Y  receptors in 
SK-N-MC cells 
Immunological characterization of P2Y receptors was 
carried out using commercially available antibodies for the 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 
subtypes. 
Several P2Y receptors are simultaneously expressed in 
SK-N-MC cells, as specific bands corresponding to P2Y1, 
P2X1
P2X4
P2X5
P2X6
P2X7
A B
C D
E F
G H
I J
Functional characterization of P2Y1 and P2X4 receptors in human neuroblastoma SK-N-MC cells 
@Real Academia Nacional de Farmacia. Spain 251 
P2Y6, P2Y11 and P2Y13 proteins can be detected in the 
western blot assays (results not shown). Again, 
immunocytochemical experiments correlated with the 
results obtained in the western blot experiments: SK-N-
MC cells showed specific inmmunostaining with 
antibodies against P2Y1, P2Y6, P2Y11 and P2Y13 receptor 
subtypes (Figure 2). No immunostaining were observed 
with the antibodies for the P2Y2, P2Y4 and P2Y12 subtypes 
(results not shown). 
 
Figure 2. P2Y receptors immunodetection in SK-N-MC cells. 
Fluorescence image of SK-N-MC cells labeled with anti-P2Y6 
(C), anti-P2Y11 (E) and anti-P2Y13 (G) antibodies. To confirm a 
specific immunoreaction, the primary antibodies used in A, C, E 
and G were pre-absorbed with their corresponding control 
peptide and immunostaining are shown in B, D, F and H, 
respectively. Scale bar= 20 µm in all micrographs. 
3.3. Characterization of functional P2 receptors by calcium 
imaging in SK-N-MC cells 
The immunodetection of different P2X subunits or P2Y 
receptors indicates the presence of the protein but does not 
give information concerning their functionality. To 
approach this specific issue, microfluorimetric techniques 
were used. 
We analyzed the response of SK-N-MC cells to the 
most commonly utilized P2 agonists by single-cell 
imaging after loading cells with the fluorescent calcium 
dye Fura-2 AM. A significant percentage of the cells (91.5 
± 1.5% of total cells, n = 240) showed transient [Ca2+]i 
increases upon application of 10 µM ADP. Response to 
ADP is likely mediated by a P2Y1 receptor, as 
demonstrated by the almost complete blockade exerted by 
the P2Y1-selective antagonist MRS2179 (10 µM, Fig. 3A). 
Other P2Y1 agonists such as 2-MeSADP (10 µM) or 
ADPβS (10 µM) were also able to elicit [Ca2+]i increases 
in the SK-N-MC cells, these responses being almost 
completely blocked by 10 µM MRS2179 (Fig. 3B,C). 
Neither UDP (100 µM) nor UTP (100 µM) elicited 
calcium responses in the SK-N-MC cells (results not 
shown), thus precluding the presence of functional 
pyrimidine receptors. 
 
Figure 3. Stimulation of the SK-N-MC cells with ADP, 2-
MeSADP or ADPβS induces intracelular transients that are 
inhibited by the P2Y1 antagonist MRS2179. Changes in the 
A B
C D
E F
G H
P2Y1
P2Y6
P2Y11
P2Y13
Javier Gualix et al. 
@Real Academia Nacional de Farmacia. Spain 252 
intracelular Ca2+ concentration were measured when cells were 
challenged with 10µM ADP (A), 10 µM 2-MeSADP (B) OR 10 
µM AdβS (C), both in the absence and in the presence of the 
selective P2Y1 antagonist, MRS 2179 (10 µM). Traces represent 
the mean of the responses measured in 156 (A), 140 (B) or 144 
(C) individual cells. Horizontal bars above traces indicate 
duration of drug applications. 
We also tested the ability of ATP (100 µM) to induce 
[Ca2+]i increases in the SK-N-MC cells. Almost all SK-N-
MC cells (96.8 ± 0.4% of total cells, n = 882) showed 
responses when challenged with this nucleotide. Thus, 
ATP was used in some of our assays as an indicator of cell 
functionality (see Figures 5A and B). Responses to 100 
µM ATP were partially blocked by MRS2179 (10 µM), the 
residual response observed in the presence of the 
antagonist being a 13.3 % of the original one (Fig 4A). 
The P2X antagonist TNP-ATP (100 µM) also acted as a 
partial inhibitor of ATP responses, reducing by 50.2 % the 
amplitude of the calcium transients elicited by the agonist 
(Fig 4B). When SK-N-MC cells were treated with both 
antagonists, MRS2179 (10 µM) and TNP-ATP (100 µM), 
responses to 100 µM ATP were completely blocked 
(results not shown). This is indicating that ATP is exerting 
its effects through the interaction with two different P2 
receptors: a P2Y1 receptor, sensitive to MRS2179, and a 
P2X receptor which is blocked by TNP-ATP. 
 
Figure 4. ATP induces calcium responses in the SK-N-MC 
cells that are inhibited by MRS2179 and TNP-ATP. Changes 
in the intracellular Ca2+ concentration were measured when cells 
were stimulated with 100 µM ATP applied alone or in the 
presence of the selective P2Y1 antagonist, MRS 2179 (10 µM, 
A), or the P2X antagonist, TNP-ATP (100 µM, B). Traces 
represent the mean of the responses obtained in 128 (A) or 94 (B) 
individual cells. Horizontal bars above traces indicate duration of 
drug applications.  
To further characterize the P2X receptor that is 
responsible for the MRS2179 resistant component of the 
ATP response, we analyze the effect of several P2X 
agonists on the SK-N-MC cells. No cells showed 
responses to either 100 µM α,β-meATP or 100 µM BzATP 
(Fig 5A). However, responses to CTP (300 µM) were 
present in a 67.6 ± 10.1% of the analysed cells (n = 396, 
Fig 5B). Moreover, both the response to CTP (300 µM) 
and the MRS2179-resistant component of the ATP (100 
µM) response were potentiated in the presence of 5 µM 
ivermectin (Fig 5B and C), a positive allosteric modulator 
of the P2X4 receptor (34, 35).  
 
Figure 5. Intracellular calcium increments evoked by 
different purinergic agonists and effect of the P2X4 
potentiator ivermectin in the SK-N-MC cells. (A) Effect of 
100 µM BzATP or 100 µM α,β-meATP on the intracellular Ca2+ 
concentration in the SK-N-MC cells. At the end of the 
experiments, cells were challenged with 100 µM ATP to test their 
A
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functionality. Traces represent the mean of the responses 
obtained in 108 individual cells. (B) SK-N-MC cells were 
stimulated with 300 µM CTP both in the absence and in the 
presence of the P2X4 positive modulator ivermectin (5 µM). At 
the end of the experiments, cells were challenged with 100 µM 
ATP to test their functionality. Traces represent the mean of the 
responses obtained in 135 individual cells that showed responses 
to CTP. (C) SK-N-MC cells were stimulated with 100 µM ATP, 
both in the absence and in the presence of the P2Y1 antagonist 
MRS2179 (10 µM), to selectively analyze the MRS2179-resistant 
component of the ATP response. Afterwards, cells were 
challenged with 100 µM ATP in the presence of MRS2179 (10 
µM) and ivermectin (5 µM), in order to analyze the effect of the 
positive modulator of the P2X4 receptor on the MRS2179-
resistant component of the ATP response. Traces are the mean of 
the responses measured in 140 individual cells. Horizontal bars 
above traces indicate duration of drug applications in all cases. 
4. DISCUSSION 
The limited biological material and the cellular 
heterogeneity of primary neuronal cultures frequently 
represent a disadvantage for the in vitro study of the 
nucleotide mediated signalling in the nervous system. The 
use of homogeneous cultured neuroblastoma cell lines that 
constitutively express P2 receptors allows avoiding these 
inconveniences, so these lines could constitute a reliable 
and convenient model with which analyze the signal 
transduction pathways and intracellular events associated 
with the activation of nucleotide receptors in neural 
tissues. 
In the present study we have investigated the presence 
of functional P2 receptors in human neuroblastoma SK-N-
MC cells by a combination of immunological and calcium 
measurement experiments. Immunological assays showed 
the expression of P2Y1, P2Y6, P2Y11 and P2Y13 receptors 
in the SK-N-MC cell line. P2X1, P2X4, P2X5, P2X6 and 
P2X7 subunits can also be detected in the SK-N-MC cells 
by means of immunocytochemical and western blot assays.  
Despite the abundant expression of P2 receptors in the 
SK-N-MC cells only a few range of P2X or P2Y agonists 
are able to elicit calcium responses. A similar feature can 
be also observed in other neuroblastoma cell types. For 
instance, murine N2a cells express a wide range of P2X 
subunits, including P2X1, P2X3, P2X4 and P2X7. 
However, of these, the P2X7 receptor was the only 
functional receptor (6). 
The finding that ADP, 2-MeSADP and ADPβS induce 
calcium increases that are inhibited by the subtype-
selective P2Y1-antagonist MRS2179 (36, 37), strongly 
support the presence of a functional P2Y1 receptor in the 
SK-N-MC cell line. ADP and its derivatives also activate 
the P2Y13 receptor (36, 38, 39), which can be 
immunologically detected in SK-N-MC cells. However if 
the calcium transient induced by these compounds were, at 
least in part, due to their interaction with a P2Y13 receptor, 
a residual response should be observed in the presence of 
MRS2179 that, at concentrations up to 100 µM, had no 
significant effect on the P2Y13 receptor (36, 38). This is 
not the case: responses to ADP and ADP derivatives are 
almost completely blocked by MRS2179, thus indicating 
that these agonists increase the intracellular calcium 
concentration due to their exclusive interaction with a 
P2Y1 receptor in the SK-N-MC cells. On the other hand, 
the lack of effect of UDP, a selective agonist at the 
pyrimidinergic P2Y6 receptor (36, 37), precludes the 
presence of functional P2Y6 receptors in the SK-N-MC 
cells, in spite of our data showing their robust expression.  
Regarding ATP, this nucleotide was also able to induce 
calcium transients in the SK-N-MC cells. The partial 
inhibition that both the specific P2Y1 antagonists 
MRS2179 and the P2X antagonist TNP-ATP (40) exert on 
the ATP responses indicates that this nucleotide is 
activating at least two different receptors in the SK-N-MC 
cells: the previously mentioned PY1 receptor, which is 
blocked by MRS2179, and a P2X receptor, inhibited by 
TNP-ATP. P2Y11 receptor, which is sensitive to ATP (36, 
37), can be also detected at the protein level in the SK-N-
MC cells. However, if ATP were activating also this 
receptor, a residual response to the agonist should be 
observed in the combined presence of MRS2179 and TNP-
ATP. This is not the case: ATP responses in SK-N-MC 
cells are completely blocked by means of a combination of 
MRS2179 and TNP-ATP. Additionally, the lack of effect 
of BzATP and UTP, both potent agonists at the P2Y11 
receptor (36, 41), also precludes the presence of functional 
P2Y11 receptors in the SK-N-MC cell line. 
We tried to establish the identity of the P2X receptor 
that is responsible for the MRS2179-resistant component 
of the ATP response. SK-N-MC cells did not respond to 
α,β-meATP or BzATP but increased their [Ca2+]i when 
challenged with CTP. Although P2X1 and P2X6 subunits 
can be immunodetected in the SK-N-MC cells, the 
presence of functional P2X1 or P2X6 channels can be 
ruled out due the lack of action of α,β-meATP, a potent 
agonist of both receptors (42-44). α,β-meATP is a weak or 
inactive agonist at the P2X5 and P2X7 receptors but, if 
these channels were functional in the SK-N-MC cells, 
responses to BzATP should be obtained, as both receptors 
are activated by this nucleotide analog (42, 45, 46). The 
pattern of agonist activity observed in the SK-N-MC cells 
is, however, consistent with the presence of a functional 
P2X4 receptor. P2X4 channels have been proved to be 
nearly insensitive to methylene-substituted ATP analogs, 
whereas they can be activated by CTP, this compound 
being a less potent agonist than ATP (42, 47). An unusual 
property of the P2X4 receptor that differentiates it from all 
other homomeric P2X channels is its potentiation by 
ivermectin. This antiparasitic agent is a positive allosteric 
modulator that specifically augments the response of P2X4 
receptor to its agonists (34, 35). SK-N-MC cells showed 
responses to CTP that increased in the presence of 
ivermectin, this being an additional evidence favouring the 
presence of a functional P2X4 receptor in the SK-N-MC 
cell line. Moreover, the residual responses to ATP in the 
presence of MRS2179 were also potentiated by ivermectin, 
which could indicate that the P2X4 receptor is responsible 
for the MRS2179-resistant component of the ATP 
response in the SK-N-MC cells. 
Javier Gualix et al. 
@Real Academia Nacional de Farmacia. Spain 254 
As SK-N-MC cells express different P2X subunits, the 
possible formation of heteromeric assemblies, in which 
P2X4 subunits were present, should be taken into 
consideration. Three different P2X4-containing 
heteromeric channels have been described so far: P2X1/4, 
P2X4/6 and P2X4/7 receptors (48-50). P2X4/7 
heteromeric receptor shares some of the pharmacological 
properties of the P2X receptor in the SK-N-MC cells, as it 
is potentiated by ivermectin (48). However there is a clear 
difference between both receptors: heteromeric P2X4/7 
receptor is activated by BzATP (48) whereas the P2X 
receptor in SK-N-MC cells has been proved to be 
insensitive to this nucleotide analog. Regarding P2X1/4 
and P2X4/6 receptors, the phenotype of such heteromers 
differs in some aspects from that of P2X4. For example, 
heteromeric P2X1/4 and P2X4/6 receptors are activated by 
low concentrations of α,β-meATP, whereas homomeric 
P2X4 receptors are relatively insensitive to this substance 
(49, 50). As P2X receptors in SK-N-MC cells appear to be 
unaffected by α,β-me-ATP, it seems more probable that 
they were formed by a homomeric combination of P2X4 
subunits rather than a heteromeric combination of P2X4 
with the P2X1 or the P2X6 subunits. However, as SK-N-
MC cells also express some additional P2X subunit, such 
as P2X5, a heteromeric association between this subunit 
and the P2X4 one can not be ruled out. 
Taken together, these pharmacological data likely 
indicate the presence of two functional P2 receptors in the 
human neuroblastoma SK-M-MC cell line: one 
metabotropic, P2Y1, and the other ionotropic, P2X4 (or a 
heteromeric channel including the P2X4 subunit). 
Responses to ADP and its derivatives will be mediated 
trough the activation of the P2Y1 receptor, although 
responses to ATP will be due to the interaction of such 
nucleotide with both the P2Y1 and the P2X4 receptors. 
CTP, on their hand, will only activate the ionotropic P2X4 
receptor. 
P2X4 receptor, which is expressed in several regions of 
the brain and spinal cord (51, 52), has received 
considerable recent attention due to its emerging role in 
the modulation of chronic inflammatory and neurophatic 
pain (53-55). There are also evidences suggesting that 
P2X4 receptors could be involved in the mechanism 
sustaining neuronal cell death caused by oxygen/glucose 
deprivation (56, 57). More recently, a role of the P2X4 
receptor in the long term potentiation in the hippocampus 
has been described (58).  
Regarding P2Y1, immunohistochemical studies showed 
an abundant and widespread distribution of this receptor 
throughout the human brain, suggesting its involvement in 
a number of important functions (59). In post-mortem 
brain sections from persons with Alzheimer’s disease, the 
P2Y1-like immunoreactivity in the hippocampus and 
entorhinal cortex was localized to neurofibrillary tangles, 
neuritic plaques and neuropil threads, which are 
characteristic Alzheimer’s structures (60). On the other 
hand, it is now recognized that interactions between G 
protein-coupled receptors can take place through the 
formation of oligomers, a process commonly referred to as 
receptor dimerization. There is evidence that P2Y1 
receptors can form both homodimers and heteromeric 
complexes with the P2Y11 or A1 receptors (61, 62). Such 
kinds of interaction will contribute to add complexity to 
the purinergic signalling 
5. CONCLUSIONS 
In summary, P2Y1 and P2X4 receptors are widespread 
in the CNS where they can participate in a number of 
different and important functions. As these receptors are 
constitutively expressed and functional in SK-N-MC cells, 
such cells can constitute a useful model with which 
analyze several aspects of the physiology of both 
nucleotide receptors. These include their regulation, 
associated intracellular signalling pathways, 
oligomerization, cross-talk with other neurotransmitter 
systems and putative implication in neurological or 
neurodegenerative disorders. 
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